FUS and BRD4 Prion-Like Low-Complexity Domains

FUS (Fused in Sarcoma, also designated Translocated in Liposarcoma [TLS], encoded on human chromosome 16p11.2 across 15 exons; 526 amino acids, ~53.4 kDa) and BRD4 (Bromodomain-Containing Protein 4, encoded on chromosome 19p13.12 across 20 exons; long isoform 1,362 amino acids, ~152 kDa) represent the two foundational biophysical archetypes of nuclear liquid–liquid phase separation (LLPS) and transcriptional condensate assembly in eukaryotic biophysics. Whereas FUS combines an N-terminal QGSY-rich prion-like low-complexity domain (PLD, residues 1–165) with C-terminal RNA-recognition (RRM), zinc-finger (ZnF), and arginine–glycine–glycine (RGG) RNA-binding modules to nucleate ribonucleoprotein (RNP) granules, spliceosome assemblies, and poly(ADP-ribose)-seeded DNA repair condensates, BRD4 pairs two N-terminal acetyl-lysine-binding bromodomains (BD1 and BD2) with a ~700-residue C-terminal proline/glutamine/serine-rich intrinsically disordered region (IDR, residues 675–1,362) that condenses Mediator (MED1) and RNA Polymerase II (Pol II) at H3K27ac-marked super-enhancers.

Together, quantitative polymer physics and structural studies of FUS and BRD4 established the "sticker-and-spacer" grammar of biomolecular condensates—explaining how reversible multivalent π–π, cation–π (Tyr–Arg), and dipolar interactions compartmentalize transcription and RNA processing at physiological concentrations (~0.5–5.0 μM), and how pathological perturbations of these same low-complexity domains drive amyotrophic lateral sclerosis (ALS) / frontotemporal dementia (FTD) amyloid maturation, FUS–DDIT3 myxoid liposarcoma and FUS–ERG leukemia chimeric oncoprotein condensates, and BRD4–NUT midline carcinoma megadomains.

FUS: Aromatic Tyrosine Stickers, Arginine Spacers, and the Saturation Concentration (csat)

Human FUS (526 residues) is a member of the FET (FUS, EWSR1, TAF15) family of nuclear RNA/DNA-binding proteins. Its primary sequence is sharply bipartite:

1. The N-Terminal Prion-Like Low-Complexity Domain (PLD / LC, residues 1–165, plus Gly-rich 166–267): Composed almost exclusively of just four polar uncharged amino acids—Glutamine (Q), Glycine (G), Serine (S), and Tyrosine (Y), arranged in 27 degenerate [G/S]Y[G/S] repeats—and virtually devoid of charged (Lys, Arg, Asp, Glu) or aliphatic hydrophobic (Leu, Ile, Val) residues. This compositional bias mirrors yeast prion domains (Sup35, Ure2), earning its classification by the PLAAC algorithm as a canonical prion-like domain (PLD).
2. The C-Terminal RNA-Binding & Nuclear Import Architecture (residues 268–526): Comprises an RNA-Recognition Motif (RRM, 285–371), three arginine–glycine-rich RGG/RG boxes (RGG1 165–267, RGG2 371–422, and RGG3 453–501, containing 37 Arginine residues and binding G-quadruplex DNA/RNA), a RanBP2-type Zinc Finger (ZnF, 422–453) coordinating Zn²⁺ to recognize GGU RNA motifs, and a C-terminal Proline–Tyrosine Nuclear Localization Signal (PY-NLS, residues 501–526).

In 2018, Rohit Pappu, Anthony Hyman, Simon Alberti, and colleagues demonstrated that phase separation of full-length FUS (which occurs spontaneously at a physiological saturation concentration of csat ≈ 1–2 μM, compared to >100 μM for the isolated PLD alone) is governed by associative polymer "sticker-and-spacer" thermodynamics. The 27 planar aromatic Tyrosine (Tyr) side chains in the N-terminal PLD and the 37 positively charged guanidinium Arginine (Arg) side chains in the C-terminal RGG domains act as complementary "stickers" that form short-range directional cation–π (Tyr–Arg, interaction energy ~ −3 to −5 kcal/mol) and planar π–π (Tyr–Tyr) non-covalent cross-links, while the intervening Gly, Ser, and Gln residues act as flexible polar "spacers" that dictate droplet viscosity and hydration.

Crucially, mutating Tyr to Ser or Arg to Lys increases csat orthogonally according to: c_sat ∝ (n_Tyr × n_Arg)⁻¹ confirming that the product of aromatic Tyr and guanidinium Arg valencies controls the spinodal and binodal phase boundary of FUS.

BRD4: Tandem Bromodomains (BD1/BD2) Coupled to the C-Terminal Super-Enhancer IDR

Whereas FUS links low-complexity phase separation to RNA and single-stranded DNA binding, BRD4 (the dominant member of the Bromodomain and Extra-Terminal [BET] family alongside BRD2, BRD3, and testis-specific BRDT) links phase separation directly to acetylated chromatin. The long oncogenic isoform of BRD4 (BRD4-L, 1,362 residues) comprises:

1. Tandem N-Terminal Bromodomains (BD1, residues 58–169; and BD2, residues 349–461): Four-helix bundles (αZ, αA, αB, αC) with a hydrophobic ZA/BC loop pocket (Asn140 in BD1; Asn433 in BD2) that specifically binds ε-N-acetylated lysine residues on histone tails (H3K27ac, H3K14ac, and di-acetylated H4K5ac/K8ac, H4K12ac/K16ac) and acetylated transcription factors (RelA/NF-κB K310ac, TWIST).
2. Extra-Terminal (ET) Domain (residues 600–678): Recruits chromatin modifiers (NSD3, JMJD6, CHD4).
3. C-Terminal Intrinsically Disordered Region (BRD4-IDR, residues 675–1,362) and P-TEFb Interaction Motif (PID, 1,325–1,362): A ~687-residue low-complexity domain enriched in Proline (~22%), Glutamine (~14%), Serine (~14%), and charged Acidic/Basic blocks.

At H3K27ac-dense super-enhancers (clusters of enhancers spanning 10–50 kb that control cell-identity genes and oncogenes like MYC), high-density chromatin binding of BD1/BD2 raises the local concentration of BRD4-IDR above its phase threshold (csat ≈ 1–5 μM). The BRD4-IDR co-condenses with the intrinsically disordered C-terminal domain of MED1 (Mediator subunit 1) and the 52-heptad-repeat C-terminal domain (CTD, YSPTSPS) of RNA Polymerase II, while the C-terminal PID of BRD4 recruits Positive Transcription Elongation Factor b (P-TEFb: CDK9–Cyclin T1) to phosphorylate Ser2 of the Pol II CTD and DSIF/NELF, releasing paused Pol II into productive transcriptional elongation.

ALS-Associated FUS Mutations (P525L) and Kapβ2 (TNPO1) Chaperoning

Under physiological conditions, nuclear FUS droplets remain dynamically liquid (exhibiting fluorescence recovery after photobleaching [FRAP] half-times of t1/2 ≈ 1–5 seconds) for two reasons: (1) high nuclear RNA concentrations buffer excessive FUS self-association (RNA-buffered re-entrant phase separation), and (2) the nuclear import receptor Karyopherin-β2 (Kapβ2 / Transportin-1, encoded by TNPO1) binds the C-terminal PY-NLS (residues 501–526) with nanomolar affinity (K_d ≈ 9.5 nM) while making secondary chaperone contacts across the RGG and QGSY domains, preventing cytoplasmic FUS condensation and importing FUS into the nucleus.

In Autosomal Dominant Amyotrophic Lateral Sclerosis Type 6 (ALS6), clustered germline missense or truncating mutations inside the C-terminal PY-NLS—most notably p.Pro525Leu (P525L, juvenile-onset aggressive ALS), p.Arg521Cys (R521C), and p.Arg495* (R495X)—reduce Kapβ2 binding affinity by 10-fold to 30-fold. Deprived of Kapβ2 nuclear import and molecular chaperoning, mutant FUS accumulates in the motor neuron cytoplasm (where RNA concentrations are lower than in the nucleoplasm) and forms persistent cytoplasmic stress granules. Over hours, thermal fluctuations within these high-density liquid droplets drive an irreversible liquid-to-solid (hydrogel/fibrillar amyloid) phase transition nucleated by cross-β cores (residues 39–95 and 112–150 of the PLD, termed LARKS—Low-complexity Aromatic-Rich Kinked Segments). In addition, PRMT1-mediated asymmetric dimethylation (aDMA) of FUS RGG arginines normally weakens Tyr–Arg cation–π strength; in sporadic Frontotemporal Lobar Degeneration (FTLD-FUS), hypomethylated FUS forms hyper-stable β-sheet aggregates even without a FUS coding mutation.

Chromosomal Translocations: FUS–DDIT3 Liposarcoma and BRD4–NUT Megadomains

In human sarcomas, leukemias, and carcinomas, chromosomal translocations hijack the phase-separating domains of FUS and BRD4 to build aberrant oncogenic transcriptional hubs:

1. FUS–DDIT3 (t(12;16)(q13;p11) in >90% of Myxoid Liposarcoma): Fuses the N-terminal FUS PLD (residues 1–165/265) directly to the full-length basic leucine-zipper (bZIP) transcription factor DDIT3 (CHOP) (paralleling EWSR1–FLI1 in Ewing sarcoma). The grafted FUS PLD undergoes multivalent phase separation at DDIT3 DNA target motifs, recruiting both Pol II and the SWI/SNF (cBAF) chromatin remodeler (ARID1A/SMARCA4) to create de novo oncogenic enhancers while blocking adipocytic CEBPA/PPARG differentiation.
2. BRD4–NUTM1 (t(15;19)(q14;p13.1) in NUT Midline Carcinoma): Fuses the N-terminal tandem bromodomains (BD1/BD2) of BRD4 to Nuclear Protein in Testis (NUTM1). NUTM1 contains acidic intrinsically disordered domains that directly recruit and allosterically activate the histone acetyltransferase p300/CBP. This creates a feed-forward phase-separation reaction: BRD4 BD1/BD2 binds H3K27ac → tethered NUTM1 recruits p300 → p300 hyper-acetylates adjacent nucleosomes → more BRD4–NUT is recruited, spreading across 100 kb to 2 Mb of chromatin ("megadomains") that sequester cellular Pol II and MED1 onto the MYC, SOX2, and TP63 loci.

Competitive Bromodomain Inhibitors (JQ1, OTX015, Pelabresib) vs. PROTAC Degraders (dBET6, ARV-825)

In 2010, James Bradner, Panagiotis Filippakopoulos, Stefan Knapp, and colleagues reported (+)-JQ1, a thienotriazolodiazepine small molecule that mimics an acetyl-lysine side chain and forms a conserved hydrogen bond with Asn140 (BD1) and Asn433 (BD2) of BRD4 (K_d ≈ 50–90 nM), competitively displacing BRD4 from H3K27ac-modified super-enhancers.

Remarkably, although JQ1 binds BRD4 at every promoter and enhancer genome-wide, low-nanomolar JQ1 preferentially collapses transcription at super-enhancer-driven oncogenes (such as MYC in multiple myeloma, AML, and NUT carcinoma) because super-enhancer condensates exhibit cooperative phase behavior near their critical threshold (c_sat): reducing the multivalent chromatin anchoring of BRD4 by ~50% drops the local concentration below c_sat, dissolving the entire super-enhancer BRD4–MED1–Pol II droplet. Even greater potency is achieved by heterobifunctional PROTAC degraders (dBET1, dBET6, ARV-825, MZ1), which link JQ1 or OTX015 to a Cereblon (CRBN) or VHL E3 ligase ligand—catalytically eliminating both the BD1/BD2 chromatin anchor and the C-terminal BRD4-IDR scaffold within 1 to 2 hours.

How does FUS initiate the earliest step of DNA double-strand break (DSB) repair within seconds of DNA damage?

Within 1 to 5 seconds of a double-strand break, chromatin-bound PARP1 synthesizes negatively charged branched poly(ADP-ribose) (PAR) polymers at the lesion (as detailed in the BRCA1 and BRCA2 article). The positively charged C-terminal RGG domains of FUS bind PAR chains with high affinity, rapidly raising the local FUS concentration above c_sat (~1 μM) to nucleate a transient liquid FUS repair condensate around the break site. This liquid FUS compartment concentrates the DDR kinases (ATM), XRCC1, and SFPQ/NONO while mechanically holding broken DNA ends together; once PARG (poly(ADP-ribose) glycohydrolase) degrades the PAR scaffold after ~10–15 minutes, the FUS droplet dissolves so downstream 53BP1 or BRCA1/RAD51 repair complexes can engage.

Why does aliphatic alcohol 1,6-hexanediol dissolve liquid FUS and BRD4 condensates but fail to dissolve aged ALS FUS fibrils?

1,6-Hexanediol is an amphiphilic aliphatic alcohol commonly used (at 1–5% w/v) as a diagnostic probe for weak hydrophobic and aromatic π–π / cation–π interactions. In freshly formed liquid FUS or BRD4–MED1 droplets, where molecules are held together by dynamic, sub-second Tyr–Arg and hydrophobic contacts, 1,6-hexanediol solvates the aromatic/hydrophobic stickers and dissolves the droplets within 30 to 60 seconds. Conversely, once mutant FUS (P525L or G156E) undergoes liquid-to-solid "aging" into cross-β amyloid fibrils stabilized by dense backbone hydrogen-bonding networks (LARKS steric zippers), 1,6-hexanediol can no longer dissociate the solid aggregates.

How do small-molecule cancer drugs selectively partition into or out of BRD4 and MED1 transcriptional condensates?

In 2020, Richard Young and colleagues demonstrated that transcriptional condensates formed by BRD4, MED1, and FUS possess distinct internal physicochemical environments enriched in aromatic and π-electron-rich residues (Tyr, Phe, Trp, Arg). Consequently, small-molecule antineoplastic drugs containing planar aromatic ring systems—including cisplatin (which platination-crosslinks DNA preferentially inside MED1 super-enhancer condensates), mitoxantrone, and tamoxifen (partition coefficients 10× to 100× higher inside the condensate than in the surrounding nucleoplasm)—concentrate selectively inside BRD4/MED1 droplets, directly influencing target engagement and acquired drug resistance (for example, ERα or BRD4 alterations that shift condensate partitioning).

1. Patel, A., Lee, H. O., Jawerth, L., et al. (2015). "A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation." Cell, 162(5), 1066–1077. https://doi.org/10.1016/j.cell.2015.07.047
2. Wang, J., Choi, J.-M., Holehouse, A. S., et al. (2018). "A molecular grammar governing the driving forces for phase separation of prion-like RNA binding proteins." Cell, 174(3), 688–699. https://doi.org/10.1016/j.cell.2018.06.006
3. Sabari, B. R., Dall'Agnese, A., Boija, A., et al. (2018). "Coactivator condensation at super-enhancers links phase separation and gene control." Science, 361(6400), eaar3958. https://doi.org/10.1126/science.aar3958
4. Filippakopoulos, P., Qi, J., Picaud, S., et al. (2010). "Selective inhibition of BET bromodomains." Nature, 468(7327), 1067–1073. https://doi.org/10.1038/nature09504